Antidepressant-like effect of sildenafil through oxytocin-dependent cyclic AMP response element-binding protein phosphorylation

Neuroscience

Volumn 200, Issue , 2012, Pages 13-18

  Matsushita, H ^a   Matsuzaki, M ^a   Han, X J ^a   Nishiki, T I ^a   Ohmori, I ^a   Michiue, H ^a   Matsui, H ^a   Tomizawa, K ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Anxiety; CREB; Depression; MAP kinase; Oxytocin; Sildenafil

Indexed keywords

BRAIN PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; OXYTOCIN; OXYTOCIN RECEPTOR; OXYTOCIN RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; EMBRYO; FEMALE; HIPPOCAMPUS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANILINE COMPOUNDS; ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAMIDES; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXPLORATORY BEHAVIOR; FEMALE; GENE EXPRESSION REGULATION; IMMOBILITY RESPONSE, TONIC; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXYTOCIN; PHOSPHORYLATION; PIPERAZINES; PURINES; RECEPTORS, OXYTOCIN; SEX FACTORS; SEXUAL BEHAVIOR, ANIMAL; SULFONES; SWIMMING;

EID: 84855198446     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.11.001     Document Type: Article

References (48)

1. Argiolas A., Gessa G.L. Central functions of oxytocin. Neurosci Biobehav Rev 1991, 15:217-231.
2. Arletti R., Bertolini A. Oxytocin acts as an antidepressant in two animal models of depression. Life Sci 1987, 41:1725-1730.
3. Bielsky I.F., Young L.J. Oxytocin, vasopressin, and social recognition in mammals. Peptides 2004, 25:1565-1574.
4. Boolell M., Gepi-Attee S., Gingell J.C., Allen M.J. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996, 78:257-261.
5. Brink C.B., Clapton J.D., Eagar B.E., Harvey B.H. Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm 2008, 115:117-125.
6. Brocardo Pde S., Budni J., Lobato K.R., Kaster M.P., Rodrigues A.L. Antidepressant-like effect of folic acid: involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway. Eur J Pharmacol 2008, 598:37-42.
7. D'Sa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord 2002, 4:183-194.
8. Drevets W.C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 2000, 126:413-431.
9. Drevets W.C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001, 11:240-249.
10. Duric V., Banasr M., Licznerski P., Schmidt H.D., Stockmeier C.A., Simen A.A., et al. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010, 16:1328-1332.
11. Ermisch A., Rühle H.J., Landgraf R., Hess J. Blood-brain barrier and peptides. J Cereb Blood Flow Metab 1985, 5:350-357.
12. Fagioli S., Rossi-Arnaud C., Ammassari-Teule M. Open field behaviours and spatial learning performance in C57BL/6 mice: early stage effects of chronic GM1 ganglioside administration. Psychopharmacology (Berl) 1991, 105:209-212.
13. Francis S.H., Corbin J.D. Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol 2005, 1:283-293.
14. Frasch A., Zetzsche T., Steiger A., Jirikowski G.F. Reduction of plasma oxytocin levels in patients suffering from major depression. Adv Exp Med Biol 1995, 395:257-258.
15. Gainer H., Wray S. Lactation and its hormonal control. The physiology of reproduction 1994, 1099-1129. Raven Press, New York. E. Knobil, J.D. Neill (Eds.).
16. Ghasemi M., Sadeghipour H., Mosleh A., Sadeghipour H.R., Mani A.R., Dehpour A.R. Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test. Eur Neuropsychopharmacol 2008, 18:323-332.
17. Gourley S.L., Wu F.J., Kiraly D.D., Ploski J.E., Kedves A.T., Duman R.S., et al. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry 2008, 63:353-359.
18. Harrison W.M., Rabkin J.G., Ehrhardt A.A., Stewart J.W., McGrath P.J., Ross D., et al. Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol 1986, 6:144-149.
19. Harvey B.H. Affective disorders and nitric oxide: a role in pathways to relapse and refractoriness?. Hum Psychopharmacol 1996, 11:309-319.
20. Insel T.R., Shapiro L.E. Oxytocin receptor distribution reflects social organization in monogamous and polygamous voles. Proc Natl Acad Sci U S A 1992, 89:5981-5985.
21. Jesse C.R., Bortolatto C.F., Savegnago L., Rocha J.B., Nogueira C.W. Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of tramadol in the rat forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1838-1843.
22. Liebenberg N., Harvey B.H., Brand L., Brink C.B. Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression. Behav Pharmacol 2010, 21:540-547.
23. Liebenberg N., Müller H.K., Fischer C.W., Harvey B.H., Brink C.B., Elfving B., Wegener G. An inhibitor of cAMP-dependent protein kinase induces behavioural and neurological antidepressant-like effects in rats. Neurosci Lett 2011, 498:158-161.
24. Liebenberg N., Wegener G., Harvey B.H., Brink C.B. Investigating the role of protein kinase-G in the antidepressant-like response of sildenafil in combination with muscarinic acetylcholine receptor antagonism. Behav Brain Res 2010, 209:137-141.
25. Matsushita H., Tomizawa K., Okimoto N., Nishiki T., Ohmori I., Matsui H. Oxytocin mediates the antidepressant effects of mating behavior in male mice. Neurosci Res 2010, 68:151-153.
26. McEwen B.S. Stress and hippocampal plasticity. Annu Rev Neurosci 1999, 22:105-122.
27. Montejo A.L., Llorca G., Izquierdo J.A., Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001, 62:10-21.
28. Neumann I.D. Alterations in behavioral and neuroendocrine stress coping strategies in pregnant, parturient and lactating rats. Prog Brain Res 2001, 133:143-152.
29. Neumann I.D. Brain oxytocin: a key regulator of emotional and social behaviors in both females and males. J Neuroendocrinol 2008, 20:858-865.
30. Numan M., Insel T.R. Hormonal and nonhormonal basis of maternal behavior. The neurobiology of parental behavior 2003, 8-41. Springer, New Jersey. M. Numan, T.R. Insel (Eds.).
31. Nurnberg H.G., Hensley P.L., Gelenberg A.J., Fava M., Lauriello J., Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 2003, 289:56-64.
32. Ozsoy S., Esel E., Kula M. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res 2009, 169:249-252.
33. Puzzo D., Sapienza S., Arancio O., Palmeri A. Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis Treat 2008, 4:371-387.
34. Ring R.H., Schechter L.E., Leonard S.K., Dwyer J.M., Platt B.J., Graf R., et al. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010, 58:69-77.
35. Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Maréchal P., Pequeux C., et al. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007, 32:407-410.
36. Sheline Y.I., Gado M.H., Kraemer H.C. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003, 160:1516-1518.
37. Sheline Y.I., Wang P.W., Gado M.H., Csernansky J.G., Vannier M.W. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996, 93:3908-3913.
38. Shin M.S., Ko I.G., Sung Y.H., Kim S.E., Kim B.K., Kim C.J., et al. Vardenafil enhances oxytocin expression in the paraventricular nucleus without sexual stimulation. Int Neurourol J 2010, 14:213-219.
39. Slattery D.A., Neumann I.D. Oxytocin and major depressive disorder: experimental and clinical evidence for links to a etiology and possible treatment. Pharmaceuticals 2010, 3:702-724.
40. Stockmeier C.A., Mahajan G.J., Konick L.C., Overholser J.C., Jurjus G.J., Meltzer H.Y., et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004, 56:640-650.
41. Tomizawa K., Iga N., Lu Y.F., Moriwaki A., Matsushita M., Li S.T., et al. Oxytocin improves long-lasting spatial memory during motherhood through MAP kinase cascade. Nat Neurosci 2003, 6:384-390.
42. 2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006, 313:536-540.
43. Zetzsche T., Frasch A., Jirikowski G.F., Murck H., Steiger A. Nocturnal oxytocin secretion is reduced in major depression. Biol Psychiatry 1996, 39:584.
44. Zhang L., Zhang Z., Zhang R.L., Cui Y., LaPointe M.C., Silver B., et al. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res 2006, 1118:192-198.
45. Zhang R., Wang Y., Zhang L., Zhang Z., Tsang W., Lu M., et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 2002, 33:2675-2680.
46. Zhang R.L., Zhang Z., Zhang L., Wang Y., Zhang C., Chopp M. Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J Neurosci Res 2006, 83:1213-1219.
47. Zhang Z., Klyachko V., Jackson M.B. Blockade of phosphodiesterase type 5 enhances rat neurohypophysial excitability and electrically evoked oxytocin release. J Physiol 2007, 584:137-147.
48. Zomkowski A.D., Engel D., Gabilan N.H., Rodrigues A.L. Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test. Eur Neuropsychopharmacol 2010, 20:793-801.